Login to Your Account

In The Clinic NEWS
Portola Pharmaceuticals Inc.'s shares (NASDAQ:PTLA) rose 16 percent higher Wednesday, climbing $4.04 to close at $29.32, after the company shared top-line data from the first of two planned phase III studies showing that andexanet alfa, its universal factor Xa inhibitor antidote, met its primary and secondary endpoints.
LONDON – Erytech Pharma SA has provided definitive phase III evidence that its technique for encapsulating L-asparaginase in red blood cells prevents allergic reactions and the generation of neutralizing antibodies, while keeping the enzyme in circulation and active for longer, in the treatment of ALL.
HONG KONG – A German-Japanese effort to develop a first-line therapy for advanced Asian hepatocellular carcinoma (HCC) recently hit an important milestone with the completion of a phase I trial and the launch of phase II development.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: